Clinical significance of NDRG3 in patients with breast cancer. (May 2017)

• Record Type: Journal Article
• Authors: Estiar, Mehrdad Asghari; Zare, Ali-Akbar; Esmaeili, Rezvan; Farahmand, Leila; Fazilaty, Hassan; Jafari, Davood; Samadi, Tannaz; Majidzadeh-A, Keivan
• Is Part Of: Future oncology. Volume 13:Number 11(2017)
• Page Start: 961
• Page End: 969
• Publication Date: 2017-05
• Subjects: breast cancer -- MYC -- NDRG; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0457
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients.Methods: Real-time quantitative PCR was performed.Results: NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3 . Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others.Conclusion: We have presented that NDRG3 might be a tumor suppressor candidate. NDRG3 downregulation might be involved in the tumorigenesis and development of invasive BC in an advanced phase of the disease.